EDMONTON, Alberta, June 28, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") announced today that 3SBio Inc. (Nasdaq:SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, has received approval from the State Food and Drug Administration ("SFDA") to conduct a multi-center phase 3 trial of voclosporin in China.
